🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,42 USD

Máx. histórico

478,48

2 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,77%

Rango 52 semanas

312,39 – 483,99

Variación hoy

+0,03%

Cierre anterior

460,28

Rango de hoy

447,04 – 462,91

Volumen hoy

2.578.799

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,69 (puede no estar actualizado)
Dividend yield
2,19% (puede no estar actualizado)
Precio objetivo analistas
409,63 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 horas
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
11/02/2016 140,76 143,49 140,04 141,46 -2,31% 2,45% 4.374.400
10/02/2016 145,21 147,13 143,96 144,81 +1,15% 2,18% 4.273.500
09/02/2016 141,02 145,63 140,82 143,16 +0,11% 3,41% 4.211.100
08/02/2016 143,50 144,57 140,16 143,00 -1,41% 3,07% 4.627.300
05/02/2016 148,93 149,39 143,69 145,04 -3,25% 3,83% 6.451.900
04/02/2016 150,50 151,96 148,80 149,91 -0,52% 2,10% 3.685.200
03/02/2016 150,50 151,18 147,07 150,69 +0,39% 2,73% 4.530.600
02/02/2016 150,48 151,49 148,48 150,11 -1,73% 2,00% 3.881.400
01/02/2016 151,31 153,72 149,34 152,75 +0,01% 2,89% 4.602.200
29/01/2016 149,40 153,00 145,25 152,73 +2,95% 5,19% 7.174.400
28/01/2016 151,10 151,71 145,42 148,35 -1,41% 4,16% 4.246.500
27/01/2016 154,89 154,89 148,87 150,47 -2,15% 3,89% 3.752.300
26/01/2016 152,78 155,23 151,09 153,78 +0,23% 2,71% 3.645.500
25/01/2016 156,18 158,00 153,00 153,43 -1,70% 3,20% 4.765.100
22/01/2016 156,45 156,96 154,24 156,08 +2,16% 1,74% 4.577.300
21/01/2016 154,75 155,02 150,24 152,78 -1,44% 3,09% 4.674.000
20/01/2016 149,00 156,84 148,05 155,02 +2,46% 5,90% 7.338.600
19/01/2016 153,45 154,62 148,23 151,30 +0,00% 4,16% 4.382.200
15/01/2016 147,69 152,30 147,69 151,30 -1,21% 3,12% 6.213.000
14/01/2016 146,02 155,30 144,57 153,16 +5,29% 7,35% 5.649.000
13/01/2016 151,14 152,83 145,28 145,46 -3,53% 5,00% 3.982.100
12/01/2016 148,43 151,24 146,92 150,79 +2,10% 2,91% 4.410.600
11/01/2016 151,33 151,59 144,17 147,69 -2,00% 4,90% 4.747.400
08/01/2016 153,12 154,86 150,46 150,71 -1,48% 2,87% 4.179.600
07/01/2016 153,06 156,45 152,89 152,98 -2,39% 2,33% 4.162.500
06/01/2016 155,01 157,93 154,90 156,72 -0,92% 1,95% 3.826.900
05/01/2016 159,00 160,21 157,25 158,17 -0,11% 1,86% 2.678.900
04/01/2016 159,00 159,22 156,09 158,34 -2,46% 1,97% 5.083.200
31/12/2015 162,15 164,11 162,05 162,33 -0,59% 1,27% 1.775.900
30/12/2015 164,63 164,75 162,91 163,29 -0,70% 1,12% 1.493.000